KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Non Operating Investment Income (2018)

Arbutus Biopharma (ABUS) has disclosed Non Operating Investment Income for 1 consecutive years, with $24.9 million as the latest value for Q2 2018.

  • Quarterly Non Operating Investment Income changed N/A to $24.9 million in Q2 2018 from the year-ago period, while the trailing twelve-month figure was $24.9 million through Jun 2019, changed 0.0% year-over-year, with the annual reading at $24.9 million for FY2018, N/A changed from the prior year.
  • Non Operating Investment Income hit $24.9 million in Q2 2018 for Arbutus Biopharma.
  • In the past five years, Non Operating Investment Income ranged from a high of $24.9 million in Q2 2018 to a low of $24.9 million in Q2 2018.